ViBA

Causal AI-based clinical and radiomic analysis for optimizing patient selection in combined immunotherapy and SABR in early-stage NSCLC: a secondary analysis of the phase II I-SABR trial.

Saad MB, Showkatian E, Verma V · Journal for immunotherapy of cancer · 2025 · Article

10.1136/jitc-2025-013074

Verified evidence

External cohort model evaluation

0f6c1d42-e4cb-55fc-b263-1f04d12a47a8
Risk and probability estimatesSurvival and mortality

Prediction source Version of record · PDF page(s) 5

Study 1d01b386-829b-58f9-8fd1-523c12ea3500 · Prediction record (JSON)

Prediction fields

Endpoint
survival_event_free__hazard_ratio · PDF page(s) 5
Evaluation scope
external_validation · PDF page(s) 1, 5
Family
clinical_outcomes · PDF page(s) 5
Measured variable
survival_event_free · PDF page(s) 5, 6
Measurement role
clinical_outcome · PDF page(s) 5
Metric
hazard_ratio · PDF page(s) 5
Result operation
survival_association · PDF page(s) 5
Role
clinical_outcome · PDF page(s) 5
Scenario
external_validation · PDF page(s) 1, 5
Unit
dimensionless · PDF page(s) 5

I-SABR-SELECT source for individualized treatment effects · Author GitHub · WuLabMDA/ISABR-SELECT S1_Train_model.py · Prediction-linked resource · PDF page 1 · Availability reported by the authors · Curated resource record